A microneedle transdermal drug delivery patch for treating rheumatoid arthritis and its preparation method

Abstract

A microneedle transdermal drug delivery patch for treating rheumatoid arthritis, comprising a base layer, a plurality of microneedles vertically fixed on the surface of the base layer and arranged at intervals from each other, the microneedles contain active pharmaceutical ingredients. During treatment, the microneedle penetrates the stratum corneum of the skin and enters the epidermis, and the drug stored in the microneedle can be released into the interstitial fluid to achieve the purpose of treatment, overcoming the natural barrier of the traditional transdermal drug delivery preparation that is difficult to break through the stratum corneum, biological Utilizing the disadvantage of being low, the transdermal delivery efficiency of the drug is greatly improved. The dissolvable microneedle patch can contain one or more active pharmaceutical ingredients for the treatment of rheumatoid arthritis, and at the same time achieve synergistic therapeutic effects; the acupuncture effect of microneedles can also achieve adjuvant therapy. The present invention also provides a preparation method of the microneedle transdermal drug delivery patch. Through the preparation method, the same dissolvable microneedle patch can contain drugs with different solubility, and can also contain a variety of drugs. Drugs realize synergistic drug administration therapy.

Description

technical field [0001] The invention relates to a microneedle transdermal drug delivery patch for treating rheumatoid arthritis and a preparation method thereof. Background technique [0002] Rheumatoid arthritis is a common autoimmune disease that can cause joint swelling, pain, deformity, and varying degrees of disability, greatly affecting the quality of life of patients. Rheumatoid arthritis is a synovial inflammatory response, including increased blood vessel distribution and permeability, the most important of which is the increase of antigen-driven CD4+ cells, which produce different cytokines through cell-to-cell contact, such as INF -γ and TNF-α, etc., and then activate monocytes, macrophages and synovial fibroblasts to produce excessive inflammatory cytokines IL-1, IL-6 and TNF-α. These cytokines are involved in the activation of endothelial cells, the activation of osteoclasts and the destruction of cartilage, etc., leading to the continuous occurrence of inflamm...

AI Technical Summary

Problems solved by technology

For example, oral administration: the selectivity of the drug is poor, which can easily lead to different degrees of gastrointestinal reactions and kidney side effects in patients, and there is a first-pass elimination effect through liver metabolism, which will reduce the efficacy of the drug; intravenous injection: the curative effect is exerted through the systemic circulation, although the drug High bioavailability, but due to poor selectivity, it may act on multiple target organs or target cells, which may cause adverse reactions and poor patient tolerance

Intra-articular injection: Although this treatment method can directly inject drugs into the lesion, multi-site intra-articular injection is complicated to operate and poorly tolerated by patients. At the same time, it requires special personnel to operate, which is expensive and unacceptable to ordinary patients.

Images